Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03281577 · ClinicalTrials.gov registry record · Phase 2
Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT03281577 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 36 participants.
The verdict
NCT03281577, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the dose-dependent effects of TAK-954 on gastric emptying time of solids in participants with diabetic or idiopathic gastroparesis assessed by scintigraphy.
Interventions
- DRUG Placebo
- DRUG TAK-954
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-01-02 |
| Est. Completion | 2019-07-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03281577
The ClinicalTrials.gov registry entry for NCT03281577 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03281577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03281577 about?
NCT03281577 is a clinical study titled "Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants". The purpose of this study is to evaluate the dose-dependent effects of TAK-954 on gastric emptying time of solids in participants with diabetic or idiopathic gastroparesis assessed by scintigraphy.
What is the current status of trial NCT03281577?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2018-01-02. Estimated completion is 2019-07-12.
What interventions are being tested in trial NCT03281577?
The interventions under investigation include: Placebo (DRUG), TAK-954 (DRUG).
Who is sponsoring clinical trial NCT03281577?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.